Advertisement

Search Results

Advertisement



Article Topics

Your search for Robert Rifkin, MD, FACP, Guest Editor matches 1 pages

Showing 1 - 1


Introduction

As expensive cancer biologics move off patent, biosimilar products are coming on board. These are highly similar versions of licensed biologics that demonstrate near-fingerprint identity to their reference products in terms of structure and potency. Biosimilars represent a major opportunity for...

Advertisement

Advertisement



;
Advertisement